BeOne Medicines (ONC) Earnings Date & Reports

Key Takeaways

• Total revenue reached $1.89 billion in the third quarter of 2026, up 33% year over year, driven by strong demand across the oncology portfolio.
• GAAP diluted earnings per American Depositary Share (ADS) climbed to $3.28 from $1.09 a year earlier, while adjusted (non-GAAP) diluted earnings per ADS rose to $4.59 from $2.65.
• BRUKINSA (zanubrutinib) global sales grew 34% to roughly $1.4 billion, with U.S. sales surpassing $1 billion in a single quarter for the first time.
• Net income increased to about $384.7 million, and free cash flow rose 34% to $474 million, underscoring improving profitability.
• Management raised its full-year 2026 revenue guidance following the better-than-expected quarter.
• For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated pages to explore the latest data and analysis.
• Explore Trending AI Robots to discover AI-driven trading strategies and market opportunities.

Earnings Context and Why It Matters

BeOne Medicines, formerly BeiGene, is a global oncology company whose commercial growth has become a central story for biotechnology investors. The third-quarter 2026 report matters because it tests whether the company can sustain the rapid expansion of its flagship cancer treatments while improving profitability at scale. Over the past year, BeOne has consistently delivered double-digit revenue growth and beaten consensus estimates, supported by rising demand for BRUKINSA and TEVIMBRA. This quarter is particularly significant given the U.S. launch of BRUKINSA's broader indications and the early uptake of newer medicines. For investors, the results offer a read on pricing, market share, margin trajectory, and cash generation in a competitive cancer-drug landscape.

Reported Results

BeOne Medicines reported third-quarter 2026 total revenue of $1,889.8 million, up 33% from $1,412.3 million in the prior-year period and ahead of analyst expectations of roughly $1.75 billion. GAAP (Generally Accepted Accounting Principles) diluted earnings per ADS were $3.28, compared with $1.09 a year ago, while adjusted diluted earnings per ADS reached $4.59, up from $2.65. Net income rose to $384.7 million from $124.8 million.

Commercial growth was broad-based. BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, generated approximately $1.4 billion in global sales, up 34% year over year, with U.S. revenue exceeding $1 billion for the first time on 36% growth. TEVIMBRA (tislelizumab), an anti-PD-1 (programmed cell death protein 1) therapy, contributed roughly $243 million, up 28%. The Amgen in-license portfolio added about $167 million, up 26%. Gross margin was approximately 88%, and free cash flow climbed 34% to $474 million, reflecting stronger operating leverage.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing data-backed signals. Whether you are evaluating a single name like BeOne Medicines or scanning entire sectors, the AI Screener provides a structured way to build and refine watchlists.

Market Reaction and Investor Sentiment

Shares of BeOne Medicines traded higher in the session following the announcement, reflecting investor enthusiasm for the revenue beat, the first-ever $1 billion U.S. quarter for BRUKINSA, and the raised full-year outlook. Sentiment heading into the report was constructive, as the company had topped estimates in several prior quarters and momentum in its core franchises remained strong. The market's positive response suggests investors viewed the results as confirmation that BeOne's growth is durable and increasingly profitable. Still, attention remains on competitive pressures, including potential biosimilar and pricing dynamics for certain in-licensed products, which could shape the stock's trajectory beyond the immediate earnings reaction.

Forward Outlook and Key Factors to Monitor

Following the third-quarter results, investors should focus on several forward-looking themes. First, the trajectory of BRUKINSA will remain the primary growth driver, with U.S. expansion, new patient starts, and duration of treatment all contributing to sustained demand. Management noted an approximate $50 million benefit from order timing in the quarter, so the fourth quarter will help clarify underlying run-rate demand.

Second, newer launches and pipeline milestones matter. TEVIMBRA continues to gain share in China and new markets, while the U.S. launch of BEQALZI and the rollout of the HERIZON regimen in first-line HER2-positive gastric cancer are early but closely watched contributors. Management has signaled that several late-stage and pivotal trials, including programs in chronic lymphocytic leukemia and hepatocellular carcinoma, could deliver key data readouts through 2027.

Third, margin and cash flow trends deserve attention. The company's expanding operating income and rising free cash flow indicate improving scalability, but continued investment in research and development (R&D) and commercial infrastructure will influence profitability. Finally, watch for any updates to the full-year guidance and the impact of foreign exchange and potential competitive pressures on in-licensed products, which management has flagged as a risk beyond 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations